|
Real-time Estimate
Cboe BZX
18:11:10 27/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 54.96 USD | -2.03% |
|
+2.72% | +25.83% |
| 08-06 | Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026 | |
| 08-05 | (EXEL) Exelixis Now Expects Fiscal 2026 Revenue Range $2.50B-$2.55B, vs. FactSet Est of $2.60B | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 13.9B | |||||
| 70.42B | |||||
| 65.4B | |||||
| 28.28B | - | ||||
| 26.57B | |||||
| 27.16B | - |
- Stock Market
- Stocks
- EXEL Stock
- Charts Exelixis, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
